Hostname: page-component-8448b6f56d-gtxcr Total loading time: 0 Render date: 2024-04-19T10:27:36.138Z Has data issue: false hasContentIssue false
  • English
  • Français

Cervical lymphadenopathy following coronavirus disease 2019 vaccine: clinical characteristics and implications for head and neck cancer services

Part of: JLO Coronavirus Collection

Published online by Cambridge University Press:  16 September 2021

A K Abou-Foul Open the ORCID record for A K Abou-Foul [Opens in a new window] ,
E Ross Open the ORCID record for E Ross [Opens in a new window] ,
M Abou-Foul Open the ORCID record for M Abou-Foul [Opens in a new window]  and
A P George Open the ORCID record for A P George [Opens in a new window]
A K Abou-Foul*
Affiliation:
Department of Otolaryngology – Head and Neck Surgery, University Hospitals of North Midlands NHS Trust, Royal Stoke University Hospital, Stoke-on-Trent, UK
E Ross
Affiliation:
Department of Otolaryngology – Head and Neck Surgery, University Hospitals of North Midlands NHS Trust, Royal Stoke University Hospital, Stoke-on-Trent, UK
M Abou-Foul
Affiliation:
Radiology Department, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Trust, UK
A P George
Affiliation:
Department of Otolaryngology – Head and Neck Surgery, University Hospitals of North Midlands NHS Trust, Royal Stoke University Hospital, Stoke-on-Trent, UK School of Medicine, Keele University, Stoke-on-Trent, UK
*
Author for correspondence: A K Abou-Foul, Department of Otolaryngology – Head and Neck Surgery, Royal Stoke University Hospital, Newcastle Rd, Stoke-on-TrentST4 6QG, UK E-mail: ahmadkamal.abou-foul@nhs.net
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

Patients with coronavirus disease vaccine associated lymphadenopathy are increasingly being referred to healthcare services. This work is the first to report on the incidence, clinical course and imaging features of coronavirus disease vaccine associated cervical lymphadenopathy, with special emphasis on the implications for head and neck cancer services.

Methods

This was a retrospective cohort study of all patients referred to our head and neck cancer clinics between 16 December 2020 and 12 March 2021. The main outcomes measured were the proportion of patients with vaccine-associated cervical lymphadenopathy, and the clinical and imaging characteristics.

Results

The incidence of vaccine-associated cervical lymphadenopathy referrals was 14.8 per cent (n = 13). Five patients (38.5 per cent) had abnormal-looking enlarged and rounded nodes with increased vascularity. Only seven patients (53.9 per cent) reported full resolution within an average of 3.1 ± 2.3 weeks.

Conclusion

Coronavirus disease vaccine associated cervical lymphadenopathy can mimic malignant lymphadenopathy and therefore might prove challenging to diagnose and manage correctly. Healthcare services may encounter a significant increase in referrals.

Keywords

COVID-19 VaccineLymphadenopathyHead And Neck NeoplasmsNeckUltrasonographyHead And Neck Cancer
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 135 , Issue 11 , November 2021 , pp. 1025 - 1030
Copyright
Copyright © The Author(s), 2021. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

A K Abou-Foul takes responsibility for the integrity of the content of the paper

References

Medicines and Healthcare products Regulatory Agency. Public Assessment Report. Authorisation for Temporary Supply, COVID-19 mRNA Vaccine BNT162b2 (BNT162b2 RNA) concentrate for solution for injection. In: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/944544/COVID-19_mRNA_Vaccine_BNT162b2__UKPAR___PFIZER_BIONTECH__15Dec2020.pdf [19 April 2021]Google Scholar
Medicines and Healthcare products Regulatory Agency. Public Assessment Report. Authorisation for Temporary Supply, COVID-19 Vaccine AstraZeneca, solution for injection in multidose container COVID-19 Vaccine (ChAdOx1-S [recombinant]). In: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/963928/UKPAR_COVID_19_Vaccine_AstraZeneca_23.02.2021.pdf [19 April 2021]Google Scholar
Medicines and Healthcare products Regulatory Agency. Public Assessment Report. Authorisation for Temporary Supply, COVID-19 Vaccine Moderna, 0.20 mg/mL dispersion for injection (COVID-19 mRNA Vaccine [nucleoside modified]). In: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/962920/Public_Assessment_Report_for_Moderna_COVID-19_vaccine.pdf [19 April 2021]Google Scholar
Medicines and Healthcare products Regulatory Agency. Coronavirus vaccine - weekly summary of Yellow Card reporting (09/12/2020 to 14/03/2021). In: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/972844/Coronavirus_vaccine_-_summary_of_Yellow_Card_reporting_14.03.21.pdf [19 April 2021]Google Scholar
Medicines and Healthcare products Regulatory Agency. COVID-19 mRNA Pfizer- BioNTech vaccine analysis print (09/12/2020 to 14/03/2021). In: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/972832/COVID-19_mRNA_Pfizer-_BioNTech_Vaccine_Analysis_Print.pdf [28 March 2021]Google Scholar
Medicines and Healthcare products Regulatory Agency. COVID-19 vaccine AstraZeneca analysis print (04/01/2021 to 14/03/2021). In: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/975786/COVID-19_AstraZeneca_Vaccine_Analysis_Print.pdf [28 March 2021]Google Scholar
SBI Recommendations for the Management of Axillary Adenopathy in Patients with Recent COVID-19 Vaccination: Society of Breast Imaging Patient Care and Delivery Committee. In: https://www.sbi-online.org/Portals/0/Position%20Statements/2021/SBI-recommendations-for-managing-axillary-adenopathy-post-COVID-vaccination.pdf [19 April 2021]Google Scholar
Özütemiz, C, Krystosek, LA, Church, AL, Chauhan, A, Ellermann, JM, Domingo-Musibay, E et al. Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology patients. Radiology 2021;300:E296–30010.1148/radiol.2021210275CrossRefGoogle Scholar
McIntosh, LJ, Bankier, AA, Vijayaraghavan, GR, Licho, R, Rosen, MP. COVID-19 vaccination-related uptake on FDG PET/CT: an emerging dilemma and suggestions for management. AJR Am J Roentgenol 2021. Epub 2021 Aug 4CrossRefGoogle ScholarPubMed
Becker, AS, Perez-Johnston, R, Chikarmane, SA, Chen, MM, El Homsi, M, Feigin, KN et al. Multidisciplinary recommendations regarding post-vaccine adenopathy and radiologic imaging: Radiology Scientific Expert Panel. Radiology 2021;300:E323–710.1148/radiol.2021210436CrossRefGoogle ScholarPubMed
Seely, JM, Barry, MH. The Canadian Society of Breast Imaging recommendations for the management of axillary adenopathy in patients with recent COVID-19 vaccination - update. Can Assoc Radiol J 2021. Epub 2021 Feb 23CrossRefGoogle ScholarPubMed
Fernández-Prada, M, Rivero-Calle, I, Calvache-González, A, Martinón-Torres, F. Acute onset supraclavicular lymphadenopathy coinciding with intramuscular mRNA vaccination against COVID-19 may be related to vaccine injection technique, Spain, January and February 2021. Euro Surveill 2021;26:210019310.2807/1560-7917.ES.2021.26.10.2100193CrossRefGoogle ScholarPubMed
Hiller, N, Goldberg, SN, Cohen-Cymberknoh, M, Vainstein, V, Simanovsky, N. Lymphadenopathy associated with the COVID-19 vaccine. Cureus 2021;13:e13524Google ScholarPubMed
Mitchell, OR, Dave, R, Bekker, J, Brennan, PA. Supraclavicular lymphadenopathy following COVID-19 vaccination: an increasing presentation to the two-week wait neck lump clinic? Br J Oral Maxillofac Surg 2021;59:384–510.1016/j.bjoms.2021.02.002CrossRefGoogle Scholar
Cunnane, M, Cheung, L, Moore, A, di Palma, S, McCombe, A, Pitkin, L. Level 5 lymphadenopathy warrants heightened suspicion for clinically significant pathology. Head Neck Pathol 2016;10:509–1210.1007/s12105-016-0733-6CrossRefGoogle ScholarPubMed
National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. NICE guideline [NG12]. In: https://www.nice.org.uk/guidance/ng12/ [12 April 2021]Google Scholar
von Elm, E, Altman, DG, Egger, M, Pocock, SJ, Gøtzsche, PC, Vandenbroucke, JP et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:80610.1136/bmj.39335.541782.ADCrossRefGoogle ScholarPubMed
Coates, EE, Costner, PJ, Nason, MC, Herrin, DM, Conant, S, Herscovitch, P et al. ; VRC 900 Study Team. Lymph node activation by PET/CT following vaccination with licensed vaccines for human papillomaviruses. Clin Nucl Med 2017;42:329–3410.1097/RLU.0000000000001603CrossRefGoogle Scholar
Burger, IA, Husmann, L, Hany, TF, Schmid, DT, Schaefer, NG. Incidence and intensity of F-18 FDG uptake after vaccination with H1N1 vaccine. Clin Nucl Med 2011;36:848–5310.1097/RLU.0b013e3182177322CrossRefGoogle ScholarPubMed
Mortazavi, S. Coronavirus disease (COVID-19) vaccination associated axillary adenopathy: imaging findings and follow-up recommendations in 23 women. AJR Am J Roentgenol 2021. Epub 2021 Aug 1110.2214/AJR.21.25651CrossRefGoogle Scholar
Cohen, D, Krauthammer, SH, Wolf, I, Even-Sapir, E. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation. Eur J Nucl Med Mol Imaging 2021;48:1854–6310.1007/s00259-021-05314-2CrossRefGoogle Scholar
Mehta, N, Sales, RM, Babagbemi, K, Levy, AD, McGrath, AL, Drotman, M et al. Unilateral axillary adenopathy in the setting of COVID-19 vaccine. Clin Imaging 2021;75:12–1510.1016/j.clinimag.2021.01.016CrossRefGoogle ScholarPubMed
Ying, M, Ahuja, A. Sonography of neck lymph nodes. Part I: normal lymph nodes. Clin Radiol 2003;58:351–810.1016/S0009-9260(02)00584-6CrossRefGoogle ScholarPubMed
Lehman, CD, D'Alessandro, HA, Mendoza, DP, Succi, MD, Kambadakone, A, Lamb, LR. Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists across specialties. J Am Coll Radiol 2021;18:843–5210.1016/j.jacr.2021.03.001CrossRefGoogle ScholarPubMed